Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Back VanItallie, TB, Nufert, TH (Oct 2003) 'Ketones: Metabolism's ugly duckling', Nutrition Reviews , 61/10, 327-41
Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript
A structured program with real support, clear guidance, and medical oversight usually beats another round of selfguided dieting
Cervical tumors overexpress matrix metalloproteinases (MMP-2, MMP-9), cathepsins, and hyaluronidasesenzymes involved in ECM degradation, invasion, and angiogenesis [203, 204]
